Received a prior IDH inhibitor.
Parts C, D, and E: patients who have received prior ipilimumab are not eligible
Patients may not have received any of the protocol agents within  years prior to randomization
Patients who have received any chemotherapy (excluding steroids) and/or RT prior to this enrollment
Patients must not have received prior intravesical BCG or intradermal BCG
Patients must not have received any prior chemotherapy, radiation therapy, or other therapy for the treatment of ALL (other than those noted below) and must not be receiving any immunosuppressive therapy; patients may not have received any prior investigational therapy within  days prior to registration; patients must not have received any monoclonal antibody therapy within  days of registration; patients may have received the following within any time prior to registration: low dose chemotherapy-including: cyclophosphamide  g/m^, oral -mercaptopurine, or oral methotrexate (other low dose chemotherapy may be allowable, however any other options not listed here should be confirmed with the study chairs), TKI therapy, steroids, hydroxyurea, leukapheresis, intrathecal chemotherapy or vincristine (vincristine sulfate)
Patients must not have received enzymeinducing anticonvulsants within  days prior to enrollment
Prior lapatinib is allowed as long as the last dose received was >  days prior to study entry and provided the patient has not received it at any time after the diagnosis of brain metastasis
Prior treatment. Patients must have received:
Patients are not required to have received or progressed on a prior therapy.
Subjects who have received prior therapy with any hypomethylating agents
Patients who have received systemic interferon (IFN)? within the previous  months prior to enrollment to the study.
Received > cycles of alkylating agent combinations.
Received prior treatment with radioimmunotherapy, (e.g. radionuclides, holmium).
Phase : Subjects with a RET rearrangement must have had disease progression after at least one prior line of systemic therapy; subjects with an ALK rearrangement may be either treatment naive or may have received prior treatment, and must have CNS disease present at baseline; subjects cannot have received more than one prior RET TKI (such as, but not limited to, vandetanib, sorafenib, sunitinib, ponatinib, or cabozantinib); subjects enrolling to the phase  portion of the trial must not have received prior alectinib therapy
Received systemic investigational drug within  weeks prior to AVB- administration or has received AVB- previously.
Patients who received any of the following within the  days before initiating study treatment:
Patients may have received prior trastuzumab therapy alone or in combination with chemotherapy; a  week washout period is required between trastuzumab treatment and first dose of afatinib
For Parts A, B, C, D, E, F, H: Have received prior therapy with a CDK/ inhibitor, Part G: Have received prior therapy with fulvestrant or any PIK and/or mTOR inhibitor (including LY); Part I: Have received prior treatment with abemaciclib in any setting.
PHASE I SUBJECTS ONLY: Prior therapy is allowed; for patients enrolled in the Phase I portion of the study, patients may have received any number of prior lines of therapy including treatment with a BRAF and/or MEK inhibitor; prior navitoclax use will not be allowed, unless the patient received <  days of navitoclax lead-in on this or another study and had to stop for reasons other than toxicity or disease progression
Patients who have received any steroids in the week prior to diagnosis except as stated in Section .. of the protocol.
Patients can have received any number of prior therapies for treatment of their uveal melanoma excluding prior treatment with an ERK inhibitor; patients who have received prior MEK inhibition or other MAPK targeted agents will be allowed on study
Patients who received prior anti-tumoral radionuclide therapy (with unsealed sources) are not eligible for the study
Patients may be newly diagnosed or have received any number of lines of prior anticancer therapy; however, patients are required to have received available therapies for their primary disease, as deemed appropriate by the treating investigator
Patients may have had treatment (chemotherapy and/or radiotherapy) or no treatment for any number of relapses prior to this recurrence\r\n* Patients must have received their last dose of myelosuppressive anticancer chemotherapy at least three () weeks prior to study registration or at least six () weeks of nitrosourea\r\n* Patients must have received their last dose of other investigational or biological agent >  days prior to study entry\r\n** For agents that have known adverse events occurring beyond  days after administration, this period should be extended beyond the time during which adverse events are known to occur; this should be discussed with the study chair\r\n* If patients received prior monoclonal antibody treatment, at least three half-lives must be elapsed by the time of treatment initiation; these patients should also be discussed with the study chair\r\n* Patients must have received their last fraction of craniospinal or focal radiation to primary tumor or other sites >  weeks ( months) prior to registration
Participants who have received prior treatment with a CHK inhibitor.
Before the first dose of study drug: a) Has received prior systemic cytotoxic chemotherapy for metastatic disease; b) Has received other targeted or biological antineoplastic therapy (e.g., erlotinib, crizotinib, cetuximab) for metastatic disease; c) Has had major surgery (< weeks prior to first dose).
Received prior treatment targeting the signaling pathway of TGF-?.
Patients must have received prior temozolomide or an alkylating agent (ex. lomustine [CCNU]/carmustine [BCNU])
Patients who have received prior systemic therapy for metastatic RCC or have previously received IL- are not eligible; patients on hydroxychloroquine (HCQ) in neoadjuvant protocols or in the past for clinical indications ARE eligible
Patients who have received prior taxanes, including weekly taxanes are allowed
Has received prior therapy with an indoleamine-pyrrole ,-dioxygenase (IDO) inhibiting agent
Prior therapy: Patients must have been receiving single agent ibrutinib therapy at the time of disease progression. Patient may have received other therapy in combination with ibrutinib earlier in the treatment course. Patients may have received other therapies after ibrutinib but stopped based on the defined wash-out periods and still meet iwCLL criteria for treatment
Patients may not have received prior cell therapy
Has not received any prior therapy for the disease
Patients having received any prior BCL inhibitor therapy
Patient received BCG treatment for UC during the  months prior to Visit .
Patients who have received mid-intensity melphalan (> mg IV) as part of prior therapy.
Received prior treatment for cancer with a camptothecin-derived agent.
Must have received prior trastuzumab, pertuzumab, and T-DM
Subject has received a prior targeted IDH inhibitor
Received any cell-based anti-AdV therapy within  weeks prior to Day  or previously received an anti-AdV vaccine at any time.
Patients must have received last BCG dose within a year of enrollment
Must not have received an antineoplastic targeted therapy within  days.
Patients who have received no prior systemic treatment
Patients having received any prior BCL inhibitor therapy
Has received prior therapy with an immunomodulatory agent.
Patients with known ROS mutations who have not received prior targeted therapy
Patients must not have received zoledronic acid (ZA) for any reason prior to the study
Patients can or cannot have receive prior therapy with hypomethylating agent but will be allocated to specific patient cohorts based on their prior exposure. Patients that had received prior hypomethylating agent therapy should have at least received  cycles of therapy and not achieved any response or had progressed after any given number of cycles
Patients may not be receiving or have received Zometa during/or within  weeks prior to treatment with Zometa
Received prior obinutuzumab.
Concurrent treatment with other anti-cancer systemic therapies is not allowed. No other concomitant intrathecal therapy with another agent will be allowed. For patients that have received other systemic therapies, the minimum wash out period is as follows:\r\n* Patients that received previous IT therapy must have received their last treatment >=  days prior to the start of treatment\r\n* Patients who have received systemic chemotherapy must have received their last treatment >=  days prior to the start of treatment\r\n* Patients who have received an approved biologic therapy (e.g. anti-PD-, anti-CTLA, IL, interferon) must have received their last treatment >=  weeks prior to the start of treatment\r\n* Patients who have been treated with an approved targeted therapy (BRAF inhibitor and/or MEK inhibitor) must have received their last treatment >=  days or  half-lives (whichever is shorter) prior to the start of treatment\r\n* Patients who have received any other investigational agents must have received their last treatment >=  days or  half-lives (whichever is shorter) prior to the start of treatment
Receiving, or received during the four weeks prior to first dose, cytotoxic treatment for their malignancy Receiving, or received during the week prior to first dose, corticosteroids for any reason
Received more than  prior systemic chemotherapy in the unresectable or metastatic setting; if the patient received  prior systemic chemotherapy, the patient is eligible; having received prior therapies for breast cancer (such as everolimus or experimental agents) does not affect eligibility for this study
The patient must have received a boost immunization with trivalent inactivated poliomyelitis (IPOL) (Sanofi-Pasteur) at least  week prior to administration of the study agent
Patients who have not completed all standard of care treatments, including surgical procedure and radiation therapy (at least  Gy)\r\n* If the MGMT promoter in their tumor is known to be unmethylated, patients are not mandated to have received chemotherapy prior to participating in this trial\r\n* If the MGMT promoter in their tumor is known to be methylated or the MGMT promoter methylation status is unknown at time of screening, patients must have received at least one chemotherapy regimen prior to participating in this trial
Insurance pre-authorization must be received
Have received standard of care frontline surgical and chemotherapy treatment (at least six cycles of platinum and taxane therapy); patients who received neoadjuvant therapy are included
Since there is no standard effective chemotherapy for patients with NF and cutaneous neurofibromas, patients may be treated on this trial without having received prior medical therapy directed at their plexiform neurofibromas (PN)
Patients must have received one course of induction treatment with BCG (- weekly doses), irrespective of the interval since last treatment; patients are allowed to have received any number of prior chemotherapy instillations\r\n* NOTE: Patients may have received prior intravesical interferon
Subjects must have received or be receiving, at time of enrollment, RVD therapy (combination therapy with lenalidomide, bortezomib, and dexamethasone); patients must have received =<  cycles of RVD at time of enrollment and must not have progressed (by IMWG criteria) on RVD; patients may have received other regimens prior to RVD if such therapy was limited to =<  cycles; patients may have received radiation therapy prior to enrollment; patients must not have received infusional chemotherapy (e.g., bortezomib/thalidomide/dexamethasone-cisplatin/doxorubicin/cyclophosphamide/etoposide [VTD-PACE] or similar regimen) prior to enrollment
Prior treatment:\r\n* Patients must not have received chemotherapy, radiation or surgical resection of malignancy within  weeks prior to the start of study drug; however, if they have received nitrosourea or mitomycin C then they should not be enrolled in the study until  weeks after therapy was last received\r\n* No limitations to number of prior therapies\r\n* Prior treatment with volasertib or any PLK inhibitor\r\n* Prior treatment with a histone deacetylase inhibitor (anti-epileptics ok)
Patients who have received prior chemotherapy
PRIOR TO LYMPHODEPLETION: Imaging results from within  days prior to enrollment into the main study (used as baseline measure for documentation of progression) before the lymphodepletion; with prior sponsor approval, these results may be obtained at a time point greater than  days from lymphodepletion if obtained per the patients standard of care and if no other chemotherapy/lymphoma treatment received between most recent scans and start of
PRIOR TO LYMPHODEPLETION: Received chemotherapy within the previous  weeks prior to lymphodepletion
Has received prior interstitial brachytherapy, implanted chemotherapy, or therapeutics delivered by local injection or convection enhanced delivery; prior treatment with Gliadel wafers will be excluded
Patients who received chemotherapy directed at the present disease
Subject has received chemotherapy within the last  weeks prior to first treatment.
Subjects who have received prior Doxil and progressed on this therapy are not eligible, but subjects may have received prior doxorubicin.
Any number of lines of prior hormone therapy are allowed\r\n* Patients with clear progression on either tamoxifen or fulvestrant should receive the alternate agent if feasible; if a patient has received both agents in the past, the drug received while on study is at the discretion of the treating physician
Have received CAR-T therapy;
Patients who have received prior chemotherapy for endometrial cancer.
Has not received chemotherapy in the last  days
For the phase II portion of the study, patients must be chemo-naive, i.e. not have received any prior chemotherapy (except hydrea or one dose of ara-C [cytarabine] =<  g) for AML or MDS; they could have received hypomethylator agents, transfusions, hematopoietic growth factors or vitamins; temporary prior measures such as apheresis or hydrea or one dose of ara-C =<  g in order to safely control hyperleucocytosis prior to enrollment
Patients must not have received prior therapy with dasatinib and temsirolimus for any indication
Patients may not have had prior SGT-. Patient who have received prior topotecan, cyclophosphamide, or both are eligible.
Patients who have received prior chemotherapy (including Gliadel wafers) for the current glioma
Study specific limitations on prior therapy:\r\n* Patients who have received poly-ICLC are eligible for this trial if all acute poly-ICLC -related toxicity has resolved\r\n* Patients must not have received pegylated interferon previously
Patients who have received prior everolimus or ceritinib
Patients who have not received any prior treatment
Patient are eligible if they have received one or more prior treatment
Patients are allowed to consent to PANGEA as long as they have received  months ( doses) or less of FOLFOX (plus trastuzumab if HER amplified) chemotherapy
Patients must have received a taxane as part of their prior treatment
Patients who have received prior chemotherapy
Patients must not have received prior bone seeking radionuclides
Subjects who have received chemotherapy within  months prior to randomization
Received no more than  prior treatment for ALL/LBL
Patients may have received other prior activating immunotherapies (i.e. checkpoint inhibitors), but must not have received them within  months prior to registration, and there must be no serious unresolved complication of therapy at the time of registration; for the purposes of this study monoclonal antibodies and antibody drug conjugates are not considered to be activating immunotherapies and there are no additional time restrictions on prior exposure to these agents (except prior brentuximab vedotin)
Patients who have received prior anti-cancer treatment within the following time frames:\r\n* Received systemic therapies less than  days prior to starting on treatment\r\n* Received radiation therapy less than  days prior to starting on treatment\r\n* Received biologic therapy less than  days prior to starting on treatment
Cohort A: patients who have received prior cytotoxic chemotherapy, such as anthracyclines and cytarabine not permitted; but prior treatment with demethylating agents (azacytidine or decitabine), lenalidomide etc ALLOWED
Patients who have received alemtuzumab or ATG within  weeks of the transplant admission
Patients who received cytotoxic drug therapy, non-cytotoxic drug therapy, or experimental drug therapy directed against the brain tumor; patients who received Gliadel wafers will be excluded; patients may have received or be receiving corticosteroids, analgesics, and other drugs to treat symptoms or prevent complications
Patients are eligible whether they have received or not prior tyrosine kinase inhibitor (TKI) therapy; for the phase I portion of the study, patients who had received prior therapy with dasatinib should have been able to tolerate the dose equivalent to the starting dose of dasatinib in the dose level at which the patient is being entered; patients who previously received dasatinib but never at the dose being proposed are eligible provided they tolerated the maximum dose they were prescribed with no grade - toxicity not responding to optimal management
Immunomodulatory treatment - patient must have received last dose >  days prior to enrollment
Patient must not have received: cimetidine within  hours prior and for the duration of the study
Patients who have received alemtuzumab within  weeks of the transplant admission, or who have recently received horse or rabbit anti-thymocyte globulin and have an anti-thymocyte globulin level of >=  ugm/ml
Patients may have received prior chemotherapy
Patients who have received prior chrysotherapy (administration of gold salts to treat rheumatoid arthritis).
Patients who received >  mg/m^ doxorubicin and have a cardiac ejection fraction on echocardiogram =< % on protocol entry are not eligible to received DA-EPOCH-R
Received prior therapy with eribulin mesylate
Patients who have received prior treatment with PTK-ADC (PF-)
Patients who have received prior immunotherapies
Patients with genomic tumor aberrations should have received prior treatment with an FDA-approved targeted therapy (if available)
Patients who have received organ transplants.
Patients who have received no less than  transfusions of RBCs;
Patient received nitrosureas within  weeks prior to the first dose.
Patient received plasmapheresis within  weeks prior to the first dose.
Have received treatment within the last  days with a drug that has not received regulatory approval for any indication at the time of study entry
Patients who have received prior treatment with a PK inhibitor
Patient who received bortezomib within  months of randomization to this study
Patients who have received standard chemotherapy with FDA approved agents within  days of entry into the protocol.
Received allogeneic BMT
Participants with newly diagnosed GBM: has received prior chemotherapy or radiotherapy for cancer of the head and neck region; has received prior treatment with Gliadel wafers or any other intratumoral or intracavitary treatment.
Have received prior NY-ESO- therapy
Patients who have received prior treatment with nintedanib or any other VEGFR inhibitor are not eligible
Histological confirmation of WM for which the patient has received at least one prior treatment; patients may have relapsed or refractory disease;(definition: relapse; patients who have received prior treatment for WM and now have disease recurrence; refractory; patients who have received anti-WM therapy and are noted to have progressive disease while on therapy, or those patients who demonstrated disease progression within  months of the last anti-WM treatment)
Patients who have received RAI within  weeks
Has received prior therapy with an anti-IDO- agent
The subject must have recovered (=< grade ) from the acute toxic effects of prior therapy\r\n* NOTES: Subjects may have received a single platinum-based cytotoxic chemotherapy regimen; subjects having received prior cytotoxic chemotherapy must have completed their treatment more than  months prior to registration; subjects may have received prior therapy with hormones or biologic agents, but such therapies must be discontinued at least  days prior to registration for protocol therapy
Have received prior treatment with an IDH inhibitor.
Have received prior treatment with trastuzumab.
Patient must not have received pegfilgrastim within  days of enrollment
Patients may have received previous NY ESO  vaccine therapy; patients who received bevacizumab or other experimental therapies are eligible for enrollment provided they have discontinued therapy (at least  weeks) prior to randomization and recovered from toxicities to less than grade 
TREATMENT: Patients who have received prior carboplatin or AZD (MK-) would not be excluded unless the two drugs were administered in combination; patients who have received prior carboplatin in combination with AZD (MK-) would still be eligible to receive other study treatment regimens based on identified genetic mutation(s), other than carboplatin plus AZD (MK-)
Patients may have received prior interferon alpha (IFN-alpha), but must not have received IFN-alpha in the -week period prior to enrollment on the trial; patients who have not received prior adjuvant therapy should be informed of the potential therapeutic benefit of IFN-alpha; previous radiation therapy, including after the surgical resection, is allowed as long as  days have elapsed between the radiation and initiation of first vaccination with NeoVax
Patients must not have received the therapies indicated below for the specified time period prior to the first day of administration of protocol therapy on this study\r\n* Myelosuppressive chemotherapy: must have received last dose at least  weeks prior to protocol therapy; this includes cytotoxic agents given on a low dose metronomic regimen\r\n* Biologic (anti-neoplastic agent) (includes retinoids): must have received last dose at least  days prior to protocol therapy\r\n* Monoclonal antibodies: must have received last dose at least  days or  half-lives, whichever is longer, prior to protocol therapy
Prior anti-disialoganglioside (GD) antibody, isotretinoin, or lenalidomide therapy:\r\n* Patients who have received prior anti-GD antibody therapy are eligible if they did not have tumor relapse/progression while receiving this therapy\r\n* Patients who have received either isotretinoin or lenalidomide are eligible, but not if they have received the two agents concomitantly
Patients who have received prior immunosuppressive therapy within  days prior to enrollment
Patients who have received prior biologic agents less than  days prior to enrollment
Arm  patients may have an unlimited number of prior therapy regimens but may not have received prior antiangiogenesis therapy except for bevacizumab (patients may not have received aflibercept, ramucirumab, cediranib, cabozantinib, or XL)
All patients must have previously received trastuzumab and a taxane, separately or in combination and have received prior therapy for metastatic disease
Patients with acute or lymphoma forms must have received at least one cycle of combination chemotherapy (with or without mogamulizumab) or interferon (with or without zidovudine and/or arsenic); individuals with chronic or smoldering acute T-cell lymphoma (ATL) are not required to have had prior treatment or could have received any number of previous courses of therapy
Must have received prior anthracyline and taxane compound therapy unless clinically contraindicated
Patients who have received prior therapy with eribulin mesylate are not eligible
Patients may have received prior bortezomib therapy.
Patients who have never received trastuzumab
Patient who has received any prior anthracyclines
Patients who have received prior treatment with a PK inhibitor or RAD (if discontinued for toxicity)
Patients that have received prior radioimmunotherapy
Patients must not have received prior therapy with PF-
Subjects must have received prior antiangiogenic therapy.
received treatment with a drug that has not received regulatory approval for any indication within  or  days of randomization for a nonmyelosuppressive or myelosuppressive agent, respectively
HER+ patients must have received pertuzumab and TDM- (ado-trastuzumab emtansine) prior to trial enrollment; unless deemed ineligible for these therapies, and with the exceptions listed below:\r\n* Patients with metastatic breast cancer who have not received prior pertuzumab are eligible if: heavily pretreated prior to Food and Drug Administration (FDA) approval of pertuzumab (//) for first-line treatment of HER+ metastatic breast cancer (MBC)\r\n* Patients with metastatic breast cancer who have not received ado-trastuzumab emtansine are eligible if: heavily pretreated prior to FDA approval of ado-trastuzumab emtansine (//) for the treatment of patients with HER+ MBC who previously received trastuzumab and a taxane separately or in combination
Before the first dose of study medication: a) Has received prior systemic cytotoxic chemotherapy for metastatic disease, b) Has received antineoplastic biological therapy (e.g., erlotinib, crizotinib, cetuximab), c) Had major surgery (< weeks prior to first dose)
Patients in the relapsed/refractory AML cohort (Cohort ), must meet all of the following criteria:\r\n* Patient must have received at least one prior Induction chemotherapy regimen for their AML;\r\n** They may have received any type of chemotherapy\r\n** Administration of hydroxyurea to control high white blood cells (WBC) prior to, during, and after registration is permitted\r\n* Relapse or refractory disease must be documented by a bone marrow examination demonstrating > % blasts in the bone marrow not attributable to another cause\r\n* Patient must NOT have received chemotherapy within  days prior to registration
Have received prior treatment with doxorubicin, epirubicin, idarubicin, and/or other anthracyclines or anthracenediones; the participant has received treatment with olaratumab or has participated in a prior olaratumab trial.
Patients who have received prior treatment with a mutant-specific IDH inhibitor (with the exception of glioma patients)
Patients who received prior systemic chemotherapy for the study cancer.
Patients on the Phase I portion may not have received ANY prior chemotherapy; patients on the Phase II portion may have received one prior cycle of any non-investigational chemotherapy; prior chemotherapy must have been completed within  days prior to registration and all toxicities must have resolved to =< grade ; patients on either portion may have received prior treatment with dexamethasone, providing total number of days of treatment was =<  days and total treatment dose was =<  mg
Has received prior therapy with vorinostat or other epigenetic agent
Patients must have received at least two or more prior courses of intravesical therapy per recommended schedules. BCG must have been one of the prior therapies administered.
Have received prior treatment with everolimus
Have received treatment with a drug that has not received regulatory approval for any indication within  or  days of randomization for a nonmyelosuppressive or myelosuppressive agent, respectively
Have received treatment with a drug that has not received regulatory approval for any indication within  or  days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively.
Patients who have received any investigational agent, chemotherapy, interferon-alfa, or -chlorodeoxyadenosine (-CdA, cladribine) within  days prior to day 
Patients may have received one or more lines of prior chemotherapy with/without rituximab (including high dose therapy plus stem cell transplant which is counted as one regimen); prior bortezomib is allowed; patients must not have received bortezomib in the past  months
Patients who received PDGFR inhibitors (imatinib, sunitinib, nilotinib, etc.) previously are excluded (patients who received PDGFR antibody based treatment however are allowed)
Patients may not have received more than one prior chemotherapy
Patients who have received any prior chemotherapy are not eligible
Received chemotherapy or biologic therapy =<  weeks prior to the start of neratinib
Patients who have received prior therapy with a TLR agonist, excluding topical agents. Patients who have received experimental vaccines or other investigational immune therapies should be discussed with the Medical Monitor to confirm eligibility.
Patients who have received prior capecitabine therapy are not eligible
Patients must not have received any drug that is a moderate or strong inhibitor of B, C, A, and C within  week prior to receiving cyclophosphamide dosing through  hours after cyclophosphamide dosing; patients must not have received any drug that is a moderate or strong inducer of A within  weeks prior to cyclophosphamide dosing
Have received treatment with a drug that has not received regulatory approval for any indication within  or  days prior to randomization of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively.
Patients who have received prior treatment with GEN-.
Have received at least one prior therapy for WM
Patients that have received systemic treatments within four weeks prior to the beginning of treatment
May not have received prior chemotherapy; if patient has received prior adjuvant therapy, must be >  months from treatment
Subject has received any chemotherapy within  days prior to randomization.
Subject has received prior treatment with fulvestrant.
May have received one or more prior treatments with chemotherapy
All patients need to have received at least one prior CNS directed therapy; there is no restriction on the number of recurrences
There is no limit on the number or type of prior chemotherapies except:\r\n* Patients must not have received prior treatment with convection enhanced delivery, other catheter based intra-tumoral treatment, or carmustine (BCNU)/Gliadel wafers\r\n* Patients with prior therapy that included stereotactic radiosurgery (including gamma-knife or cyber-knife) during therapy for newly diagnosed or recurrent disease, or re-irradiation of any type, must have confirmation of true progressive disease rather than radiation necrosis based upon surgical documentation of recurrent/progressive disease; imaging with magnetic resonance (MR)Spectroscopy, MRPerfusion, positron emission tomography (PET), or other techniques is not adequate to exclude radiation necrosis for this study\r\n* Patients may not have received prior treatment with an agent designed to inhibit mTOR or PIK/AKT including, but not limited to, temsirolimus, rapamycin (sirolimus), RAD (everolimus), other rapalogs, BKM, or perifosine; any question regarding the definition of an agent designed to inhibit mTOR or PIK/AKT targeting should be discussed with the sponsor\r\n* Patients may not have received prior treatment with direct VEGF/VEGFR inhibitors such as bevacizumab (Avastin), aflibercept (VEGF-Trap), cediranib (AZD), trebananib (AMG ), or XL- (Cabozantinib)
Patients who have received prior treatment with a phosphatidylinositol-,-bisphosphate -kinase, catalytic subunit alpha (PK) inhibitor
Subjects must have received at least one prior treatment regimen\r\n* Subjects that have received a prior Brutons agammaglobulinemia tyrosine kinase (BTK) inhibitor or cyclin-dependent kinases  and  (CDK/) inhibition are ineligible\r\n* Subjects that have undergone prior allogeneic stem cell transplantation will only be eligible if the transplant occurred at least  year prior to study entry, the patient is no longer taking any immunosuppressive therapy, and there are no significant ongoing transplant-related adverse effects\r\n* Subjects must not have received chemotherapy =<  days prior to first administration of study treatment, monoclonal antibody =<  weeks prior to first administration of study treatment, and/or radiotherapy or other investigational agents =<  weeks prior to first administration study treatment unless the subjects tumor has progressed on the previous therapy and the investigator believes that the patient should not postpone further therapy and, all treatment-related toxicities have resolved to Common Terminology Criteria for Adverse Events (CTCAE) version (v)  =< grade ; subjects may be receiving equivalent to prednisone at a maximum dose of  mg/day orally
Patients who have received prior chemotherapy for any abdominal or pelvic tumor are excluded; patients who have received neoadjuvant chemotherapy prior to their initial debulking are excluded; patients may have received prior adjuvant chemotherapy for breast cancer
Have received treatment with a drug that has not received regulatory approval for any indication within  or  days prior to randomization of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively
Patients may not have received prior interferon, either systemic or intra-cystic
Patients must not have received prior treatment with pazopanib or topotecan
Patients with colon cancer (cohort A and B) must have received at least  prior cancer therapy regimens; patients with other cancer types (cohort C) must have received at least  prior cancer therapy regimen; patients in cohort D must have received at least  prior cancer therapy regimen; patients must have progressive disease on study entry
Have received prior therapy with an immunomodulatory agent, a proteosome inhibitor, and glucocorticoids
Patient must not have received prior temozolomide, dacarbazine (DTIC), or capecitabine, or -FU (fluorouracil) therapy
Patients who have received prior chemotherapy (including Gliadel wafers) for the current glioma
Patients must not have received prior therapy other than standard chemoradiation according to Stupp et al and Gliadel
Participants may not have received any prior camptothecin, including but not limited to: topotecan, irinotecan
Patients who received chemotherapy directed at the present disease
For dose escalation cohorts - subjects who received prior Sunitinib or Pazopanib and required permanent discontinuation due to toxicity or required dose reduction or delay during the first  weeks of therapy due to toxicity, or received both prior Sunitinib and Pazopanib
Patients are eligible even if they have not received prior treatment; they are also eligible if they have received prior treatment, and any number of treatments is allowed
Participants may have received prior hydroxyurea but may not be currently being treated with hydroxyurea at the time of study initiation
Have received treatment with a drug that has not received regulatory approval for any indication within  or  days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively
Patients must not have received prior Gliadel wafers
Patients who have received prior treatment with implanted radiotherapy or chemotherapy sources such as wafers of polifeprosan  with carmustine
Received other recent antitumor therapy
Patients who have received prior therapy with ADXS-
For Ph+ ALL patients, received corticosteroids within  hours before the first dose of ponatinib; or vincristine within  days prior to the first dose of ponatinib; or received other chemotherapy within  days prior to the first dose of ponatinib.
Glioblastoma disease-specific concerns: Patients must have received cytotoxic drug therapy, non-cytotoxic drug therapy, or experimental drug therapy directed against the brain tumor; patients who received Gliadel wafers will be excluded; patients may have received or be receiving corticosteroids, AED's, analgesics, and other drugs to treat symptoms or prevent complications
Follicular lymphoma patients must have received at least  prior lines of therapy; patients are eligible regardless of whether they have received an autologous transplant
Received prior treatment with a hypomethylating agent, except as allowed in Exclusion Criterion .b
Patients must not have received prior Gliadel wafers
Patients must not have received systemic chemotherapy or monoclonal antibody therapy within  weeks of study enrollment; patients who have previously received bolus nelarabine are still eligible; hydroxyurea or corticosteroids for control of blood counts is allowed, but must be discontinued  hours prior to initiating nelarabine
Patients who have received any investigational agent, chemotherapy, interferon-?, or -chlorodeoxyadenosine (-CdA, cladribine) within  days prior to first dose
Last dose of prior chemotherapy received less than  weeks prior to randomization
Relapse patients should have NOT received chemotherapy for  weeks, and no patient should have received nitrosoureas (melphalan, lomustine [CCNU] or mustard); no patient should have received radiation therapy in the previous  days
Patients who received DEPDC, MPHOSPH, URLC, CDCA, or KOC peptide vaccines before
Patients who have received alemtuzumab within  weeks of transplant admission, or who have recently received horse or rabbit anti-thymocyte globulin (ATG) and have ATG levels of >=  ugm/ml
Patients who received steroids more than  hours prior to study enrollment are eligible but will be analyzed separately
Patients who have received prior treatment with a PK inhibitor
Patients who have received prior immunotherapies
Patients who have received prior chemotherapy are allowed, provided they have been off systemic therapy for  days and all acute toxicities have resolved to less than grade ; patients who have received paclitaxel within  months of study entry and have developed documented progressive disease despite therapy
Received prior HD IL- therapy.
Patients who have received chemotherapy within  days prior to the cryoablation procedure
Received maintenance Temozolomide
Patients with nasal NK lymphoma who received local RT less than  weeks prior to randomization.
Patients with tMF who received  systemic single-agent CT (except methotrexate) prior to transformation.
Has never received cetuximab or panitumumab, and has not received any treatment for colorectal cancer within  days prior to the first dose of study treatment under this protocol;
Parts A and B only: Has received a prior course of axitinib.
Subjects must have received adequate prior therapy including at a minimum:
Prior therapy with bortezomib is allowed; patients who have received prior bortezomib therapy must have received bortezomib >  months ago, and must have shown some response; patients that did not respond to prior bortezomib therapy are not eligible
Have received at least one prior therapy. Patients who are over age  and have not received therapy for AML are also eligible, if they are not candidates for induction chemotherapy
Participants who received prior treatment with a hypomethylating agent
Have received treatment with any drug that has not received regulatory approval for that indication within the  days prior to study entry
Patients has received prior treatment with LEE.
Patient has received prior treatment with ceritinib.
Received Tivantinib as prior therapy
Any number of prior chemotherapies or biological therapies are allowed, patients are required to have prior treatment with pertuzumab and ado-trastuzumab emtansine with the exceptions listed below: \r\n* Metastatic patients who have not received prior pertuzumab are eligible if: heavily pretreated prior to Food and Drug Administration (FDA) approval of pertuzumab (-June-) for first line treatment of HER+ MBC\r\n* Metastatic patients who have not received ado-trastuzumab emtansine are eligible if: heavily pretreated prior to FDA approval of ado-trastuzumab emtansine (-Feb-) for the treatment of patients with HER+ MBC who previously received trastuzumab and a taxane, separately or in combination
Last received ONT- a maximum of  months (unless approved by the medical monitor) prior to receiving the first dose of maintenance or retreatment cohort therapy
Has received antibiotic therapy for Gram-negative pneumonia for greater than  hours at the time of randomization
Received one prior cycle of fulvestrant within  days of randomization are eligible.
Subjects must have received an alkylating agent unless contraindicated; subjects may have received these agents alone or in combination with other myeloma treatments
Received at least  weeks of one prior sorafenib containing systemic therapy and then experienced documented radiographic disease progression; or inability to tolerate prior therapy received for at least a minimum period of time.
Received other recent antitumor therapy
Patients who have received prior biologic agents less than  weeks prior to enrollment
Patients who have received prior interferon or IL- therapy less than  weeks prior to enrollment
Must have been receiving or have received crizotinib
Received treatment with an investigational drug, which has not received regulatory approval for any indication, within  days of study treatment with DKN-
Patients who have received prior treatment with cyclophosphamide and topotecan are eligible if they did not have tumor relapse/progression while receiving this combination.
Patients with NF will only be eligible if complete tumor resection is not considered to be feasible without substantial risk or morbidity\r\n* Patients may be treated on this trial without having received prior medical therapy directed at their PN\r\n* There will be no limit to number of prior myelosuppressive regimen for PN or other tumor manifestations associated with NF such as optic glioma\r\n* Patients who have received previous investigational agents or biologic therapy, such as tipifarnib, pirfenidone, peginterferon alfa-b (Peg-Intron), sorafenib, imatinib, or other targeted therapies are eligible for enrollment; at least  weeks must have elapsed since receiving medical therapy directed at the PN; patients who received prior medical therapy for their PN must have recovered from the acute toxic effects of all prior therapy to =< grade  before entering this study\r\n* Growth factors that support platelet or white cell number or function must not have been administered within the  days prior to enrollment\r\n* At least  weeks must have elapsed prior to enrollment since the patient received any prior radiation therapy\r\n* At least  weeks must have elapsed since any surgeries, with evidence of good wound healing
Have received any prior treatment with an IDH inhibitor.
All patients must have received at least one standard chemotherapy or chemoradiotherapy
Patients must have received adequate prior alkylator therapy
Patients who have received prior treatment with a PK inhibitor
Has received prior taxane therapy
Have received treatment within  days of the initial dose of study drug with an experimental agent for noncancer indications that has not received regulatory approval for any indication.
received Avastin
patients who received dasatinib within  days of starting study drug
patients who received imatinib within  days of starting study drug
Patients who have received prior Yttrium- radioembolization
Subject who received any other systemic anticancer treatment after parent study entry (radiation to local areas such as bone or brain if received in the parent ASP study is permitted).
Patients may have received prior chemotherapy for advanced disease including either capecitabine or temozolomide single agent as long as it did not include combination of capecitabine and temozolomide
Patients who have tested positive for a v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation may have received prior BRAF inhibitor therapy as a prior line of systemic therapy; patients may have received up to  prior lines of therapy with a checkpoint inhibitor (CPI), which may have included pembrolizumab, nivolumab, or ipilimumab; these agents may have been administered as single-agent treatment, in combination with each other, or in combination with other agents; patients who have received prior treatment with ipilimumab must have relapsed after achieving a response to prior ipilimumab treatment; this response may have been achieved with ipilimumab administered as single-agent therapy or in combination with another treatment; patients who have received prior treatment with pembrolizumab or nivolumab must have progression of disease after at least  doses of either drug alone or in combination with other agents
Patients who have previously received anti CD (agonistic) therapy prior adjuvant interferon (IFN), is allowed if last dose was received at least  months from enrolling to protocol
Subjects who have received prior oncolytic therapy or prior therapy with and toll-like receptor (TLR) agonist including topical agents; subjects that have received experimental vaccines or other immune therapies should be discussed with the medical monitor or the primary investigator (PI) to confirm eligibility
Prior therapy:\r\n* Patients must have received at least one prior standard cytotoxic regimen such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (CHOP) or doxorubicin hydrochloride, etoposide phosphate, vincristine sulfate, cyclophosphamide, and prednisone (EPOCH) - unless they were not candidates for this therapy\r\n* Patients must have received prior brentuximab vedotin - unless they were not candidates for this therapy\r\n* Patients must have received prior autologous stem cell transplant unless they refused or were not candidates for stem cell transplant
Prior treatment:\r\n* Patients must not have received chemotherapy, radiation or surgical resection of malignancy within  weeks prior to the start of study drug; however, if they have received nitrosourea or mitomycin C then they should not be enrolled in the study until  weeks after therapy was last received\r\n* No limitations to number of prior therapies\r\n* Prior therapy with other ALK inhibitor investigational agents with the exception of crizotinib (i.e., prior treatment with crizotinib is allowed)
Patients with lymphomas that are felt to be incurable with any therapy and for whom there are no standard treatments that would be anticipated to be necessary or beneficial within the next  months; these patients can have received any amount of prior chemotherapy to enter this trial
Have received cancer treatment that includes chemotherapy for at least  months
Subject has received prior therapy with a BH mimetic.
Having received Ayurvedic treatment within  months of study enrollment.
Has received voriconazole within  days prior to starting study therapy
Received sirolimus within the  days prior to starting study as voriconazole is a potent inhibitor of sirolimus metabolism
Has received the full dose of CTX over the course of their treatment
Received filgrastim (GCSF) treatment within one month of enrollment
Have received at least one prior therapy for WM
Patients who have received chemotherapy within  weeks of first fenretinide treatment, or who have received investigational drugs within  weeks of first fenretinide treatment. Patients must have otherwise recovered from toxicities of prior therapy.
Patient must not have received chemotherapy within  weeks of initiation of PCI
Received colposcopy of cervix within TWO years
Received Pap test within ONE year
Received rolapitant within  days prior to study enrollment
Patients who have received prior romidepsin use are eligible
Received chemotherapy for treatment of childhood cancer
Patients who have received targeted agents or systemic potentially radiosensitizing chemotherapy within  weeks of lung SBRT start
Patients who have received no prior therapy are eligible, as well as those who have received prior treatment
Patients who may not have received trastuzumab within the prior  months for any other reason
Participants who have received trastuzumab within the prior  days
Patients who have received prior chemotherapy for any abdominal or pelvic tumor are excluded; patients who have received neoadjuvant chemotherapy prior to their initial debulking are excluded; patients may have received prior adjuvant chemotherapy for breast cancer
Has received prior treatment with enhancer of zeste homolog (EZH) inhibitor
Participants who received biopsy only or have received more than  prior courses of radiation for meningioma
Women should have received no prior therapy for their disease
Participants with HCC must have received prior sorafenib therapy. ICC participants must have received prior platinum (cisplatin or oxaliplatin) based therapy unless contraindicated.
Must have received at least  prior approved immunotherapy or chemotherapy; however, not within  days of the initial dose of study drug. May have received prior radiotherapy for their malignancy.
Subjects must not have received BLZ- within  days prior to re-treatment
Subjects must have received adequate prior therapy including at a minimum:
Has received prior therapy with any taxane chemotherapy